IFW

DOCKET NO.: P0453.70112US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Boyd et al.
Serial No.:	10/821,813
Confirmation No.:	Not Yet Assigned
Filed:	April 8, 2004
For:	THE USE OF METHYLNALTREXONE TO TREAT IRRITABLE BOWEL SYNDROME
Examiner:	Not Yet Assigned
Art Unit:	Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 16 day of June, 2004.

Kristin J. Ketelhut

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

[X] Information Disclosure Statement
[X] PTO Form 1449 with cited references
[X] Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Boyd et al., Applicant

By: Edward R Gates

Edward R. Gates, Reg. No.: 31,616
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617)646-8000

Docket No. P0453.70112US01
Date: June 16, 2004
x07/08/04x

DOCKET NO: P0453.70112US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Boyd et al.
Serial No:	10/821,813
Confirmation No:	Not Yet Assigned
Filed:	April 8, 2004
For:	THE USE OF METHYLNALTREXONE TO TREAT IRRITABLE BOWEL SYNDROME
Examiner:	Not Yet Assigned
Art Unit:	Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 16 day of June, 2004.

Kristin J. Ketelhut

Kristin J. Ketelhut

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed within three months of the filing date of a National Application other than a continued prosecution application under 37 C.F.R. §1.53(d).

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

Docket No.	Serial No.	Filing Date	Inventor(s)
P0453.70109US00	**10/163,482**	**June 5, 2002**	**Moss et al.**
P0453.70110US00	**10/278,630**	**October 23, 2002**	**Foss et al.**
P0453.70110US01	**10/779,129**	**February 12, 2004**	**Foss et al.**
P0453.70113US00	**10/357,669**	**February 4, 2003**	**Foss et al.**
P0453.70113US01	**10/779,128**	**February 12, 2004**	**Foss et al.**
P0453.70113US02	**10/778,268**	**February 12, 2004**	**Foss et al.**
P0453.70113US03	**10/785,320**	**February 12, 2004**	**Foss et al.**
P0453.70113US04	**10/785,668**	**February 24, 2004**	**Foss et al.**
P0453.70114US00	**10/358,560**	**February 5, 2003**	**Foss et al.**
P0453.70115US01	**10/821,811**	**April 8, 2004**	**Sanghvi et al.**
P0453.70116US01	**10/821,809**	**April 8, 2004**	**Sanghvi et al.**

The following are remarks concerning the other information cited:

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;

3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
Boyd et al., *Applicant*

By: Edward R Gates

Edward R. Gates, Reg. No. 31,616
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. P0453.70112US01
Date: June 16 2004
X07/08/04X

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/821,813	ATTY. DOCKET NO.: P0453.70112US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: April 8, 2004	CONFIRMATION NO.: Not Yet Assigned
	APPLICANT: Boyd et al.	
Sheet 1 of 6	GROUP ART UNIT: Not Yet Assigned	EXAMINER: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	2001/0018413	A1	Crain, *et al.*	08-30-2001
	A2	2002/0028825	A1	Foss, *et al.*	03-07-2002
	A3	2001/0033865	A1	Oshlack, *et al.*	10-25-2001
	A4	2001/0036476	A1	Oshlack, *et al.*	11-01-2001
	A5	2001/0047005	A1	Farrar, *et al.*	11-29-2001
	A6	4,176,186		Goldberg, *et al.*	11-27-1979
	A7	4,719,215		Goldberg	01-12-1988
	A8	4,861,781		Goldberg	08-29-1989
	A9	4,987,136		Kreek, *et al.*	01-22-1991
	A10	5,102,887		Goldberg	04-07-1992
	A11	5,270,328		Cantrell, *et al.*	12-14-1993
	A12	5,472,943		Crain, *et al.*	12-05-1995
	A13	5,512,578		Crain, *et al.*	04-30-1996
	A14	5,767,125		Crain, *et al.*	06-16-1998
	A15	5,811,451		Minoia, *et al.*	09-22-1998
	A16	5,866,164		Kuczynski, *et al.*	02-02-1999
	A17	5,958,452		Oshlack, *et al.*	09-28-1999
	A18	5,972,954		Foss, *et al.*	10-26-1999
	A19	6,096,756		Crain, *et al.*	08-01-2000
	A20	6,194,382	B1	Crain, *et al.*	02-27-2001
	A21	6,261,599	B1	Oshlack, *et al.*	07-17-2001
	A22	6,274,591	B1	Foss, *et al.*	08-14-2001
	A23	6,395,705	B2	Crain, *et al.*	05-28-2002
	A24	6,419,959	B1	Walter, *et al.*	07-16-2002
	A25	6,451,806	B2	Farrar	09-17-2002
	A26	6,559,158	B1	Foss, *et al.*	05-06-2003
	A27	6,608,075	B1	Foss, *et al.*	08-19-2003
	A28	RE36,547		Crain, *et al.*	02-01-2000
	A29	2002/0188005	A1	Farrar, *et al.*	12-12-2002

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B1	AU	610,561		Shelley	08-17-1988	
	B2	CA	1,315,689		The University of Chicago	04-06-1993	
	B3	EP	0278821	A1	Shelly (Abstract)	08-17-1988	

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/821,813	ATTY. DOCKET NO.: P0453.70112US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: April 8, 2004	CONFIRMATION NO.: Not Yet Assigned
	APPLICANT: Boyd et al.	
Sheet 2 of 6	GROUP ART UNIT: Not Yet Assigned	EXAMINER: Not Yet Assigned

	B4	EP	0352361	A1	The Rockefeller University	01-31-1990	
	B5	EP	278,821	A1	Marc Yves Shelly (Derwent Abstract)	08-17-1988	
	B6	EP	306,575	B1	The Univ. of Chicago	03-15-1989	
	B7	EP	352,361	A1	The Rockefeller University	01-31-1990	
	B8	EP	760,661	B1	Minoia, *et al.*	12-30-1998	
	B9	JP	2,625,457	B2	Goldberg (Derwent Abstract)	07-02-1997	
	B10	NZ	222,911		The Univ. of Chicago	12-14-1987	
	B11	WO	83/03197	A1	The Rockefeller University	09-29-1983	
	B12	WO	88/05297	A1	Shelly	07-28-1988	
	B13	WO	95/31985	A2	Minoia, *et al.*	11-30-1995	
	B14	WO	97/33566		Alza Corp.	09-18-1997	
	B15	WO	98/25613		Klinge Pharma GmbH	06-18-1998	Yes
	B16	WO	01/13909	A2	Critical Care Pharm.	03-01-2001	
	B17	WO	01/37785	A2	Adolor Corp.	05-31-2001	
	B18	WO	01/41705	A2	Adolor Corp.	06-14-2001	
	B19	WO	01/42207	A2	Adolor Corp.	06-14-2001	
	B20	WO	01/85257	A2	Pain Therapeutics, Inc..	11-15-2001	
	B21	WO	02/060870	A2	Adolor Corp.	08-08-2002	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C1	AKINBAMI et al., Effect of a peripheral and a central acting opioid antagonist on the testicular response to stress in rats. Neuroendocrinology. 1994 Apr;59(4):343-8.		
	C2	AMIN et al., Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response. Anesth Analg. 1994 Apr;78(4):701-5.		
	C3	AMIR, Naloxone improves, and morphine exacerbates, experimental shock induced by release of endogenous histamine by compound 48/80. Brain Res. 1984 Apr 9;297(1):187-90.		
	C4	AMIR et al., Endorphins in endotoxin-induced hyperglycemia in mice. Arch Toxicol Suppl. 1983;6:261-5.		
	C5	ARGENTIERI et al., Interaction of the opiate antagonist, naltrexone methyl bromide, with the acetylcholine receptor system of the motor end-plate. Brain Res. 1983 Oct 31;277(2):377-9.		
	C6	BARATTI et al., Brain opioid peptides may participate in the reversal of pentylenetetrazol-induced amnesia. Methods Find Exp Clin Pharmacol. 1990 Sep;12(7):451-6.		
	C7	BEDINGFIELD et al., Methylnaltrexone attenuates taste aversion conditioned by low-dose ethanol. Alcohol. 1998 Jan;15(1):51-4.		
	C8	BIANCHETTI et al., Quaternary derivatives of narcotic antagonists: stereochemical requirements at the chiral nitrogen for in vitro and in vivo activity. Life Sci. 1983;33 Suppl 1:415-8.		
	C9	BIANCHI et al., Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity. Life Sci. 1982 May 31;30(22):1875-83.		
	C10	BICKEL, Stimulation of colonic motility in dogs and rats by an enkephalin analogue pentapeptide. Life Sci. 1983;33 Suppl 1:469-72.		
	C11	BLANK et al., Central, stereoselective receptors mediate the acute effects of opiate antagonists on luteinizing hormone secretion. Life Sci. 1986 Oct 27;39(17):1493-99.		
	C12	BRIX-CHRISTENSEN et al., Endogenous morphine is produced in response to cardiopulmonary bypass in neonatal pigs. Acta Anaesthesiol Scand. 2000 Nov;44(10):1204-8.		
	C13	BROWN et al., Opiate antagonists: central sites of action in suppressing water intake of the rat. Brain Res. 1981 Sep 28;221(2):432-6.		

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/821,813	ATTY. DOCKET NO.: P0453.70112US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: April 8, 2004	CONFIRMATION NO.: Not Yet Assigned
	APPLICANT: Boyd et al.	
Sheet 3 of 6	GROUP ART UNIT: Not Yet Assigned	EXAMINER: Not Yet Assigned

	C14	BROWN et al., Reversal of morphine-induced catalepsy in the rat by narcotic antagonists and their quaternary derivatives. Neuropharmacology. 1983 Mar;22(3):317-21.		
	C15	BROWN et al., The use of quaternary narcotic antagonists in opiate research. Neuropharmacology. 1985 Mar;24(3):181-91. Review.		
	C16	CALCAGNETTI et al., Quaternary naltrexone reveals the central mediation of conditional opioid analgesia. Pharmacol Biochem Behav. 1987 Jul;27(3):529-31.		
	C17	CHANG et al., An antiabsorptive basis for precipitated withdrawal diarrhea in morphine-dependent rats. J Pharmacol Exp Ther. 1984 Feb;228(2):364-9.		
	C18	CULPEPPER-MORGAN et al., Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther. 1992 Jul;52(1):90-5 (ABSTRACT ONLY).		
	C19	EISENBERG, Effects of naltrexone on plasma corticosterone in opiate-naive rats: a central action. Life Sci. 1984 Mar 19;34(12):1185-91.		
	C20	FERNANDEZ-TOME et al., Interaction between opioid agonists or naloxone and 5-HTP on feeding behavior in food-deprived rats. Pharmacol Biochem Behav. 1988 Feb;29(2):387-92.		
	C21	FOSS, A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg. 2001 Nov;182(5A Suppl):19S-26S. Review.		
	C22	FOSS et al., 1995 Annual scientific meeting of the American Society of Anesthesiologists. Atlanta, Georgia, October 21-25, 1995. Abstracts. Anesthesiology. 1995 Sep;83(3A Suppl):A361.		
	C23	FOSS et al., Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother Pharmacol. 1998;42(4):287-91.		
	C24	FOSS et al., Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J Clin Pharmacol. 1997 Jan;37(1):25-30.		
	C25	FOSS et al., Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J Clin Pharmacol. 1993 Aug;33(8):747-51.		
	C26	FOSS et al., Effects of methylnaltrexone on morphine-induced cough suppression in guinea pigs. Life Sci. 1996;59(15):PL235-8.		
	C27	FOSS et al., Methylnaltrexone reduces morphine-induced postoperative emesis by 30%. Anesth Analg. 1994;78:S119.		
	C28	FRANCE et al., Comparison of naltrexone and quaternary naltrexone after systemic and intracerebroventricular administration in pigeons. Neuropharmacology. 1987 Jun;26(6):541-8.		
	C29	FRANCE et al., Intracerebroventricular drug administration in pigeons. Pharmacol Biochem Behav. 1985 Nov;23(5):731-6.		
	C30	FRIEDMAN et al., Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother. 2001 Jan;35(1):85-91. Review.		
	C31	GMEREK et al., Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J Pharmacol Exp Ther. 1986 Jan;236(1):8-13.		
	C32	HEIN et al., Pharmacological analysis of the discriminative stimulus characteristics of ethylketazocine in the rhesus monkey. J Pharmacol Exp Ther. 1981 Jul;218(1):7-15.		
	C33	HOWD et al., Naloxone and intestinal motility. Experientia. 1978 Oct 15;34(10):1310-1.		
	C34	JALOWIEC et al., Suppression of juvenile social behavior requires antagonism of central opioid systems. Pharmacol Biochem Behav. 1989 Jul;33(3):697-700.		
	C35	JANKOVIC et al., Quaternary naltrexone: its immunomodulatory activity and interaction with brain delta and kappa opioid receptors. Immunopharmacology. 1994 Sep-Oct;28(2):105-12.		
	C36	KAUFMAN et al., Role of opiate receptors in the regulation of colonic transit. Gastroenterology. 1988 Jun;94(6):1351-6.		
	C37	KIM et al., Assay for methylnaltrexone in rat brain regions and serum by high-performance liquid chromatography with coulometric electrochemical detection. Chromatographia. 1989 Oct;28(7-8):359-63.		
	C38	KINSMAN et al., Effect of naloxone on feedback regulation of small bowel transit by fat. Gastroenterology. 1984 Aug;87(2):335-7.		
	C39	KOBLISH et al., Behavioral profile of ADL 8-2698, a novel GI-restricted μ opioid receptor antagonist. Society for Neuroscience Abstracts. 2001;27(2):2407.		
	C40	KOBYLECKI et al., N-Methylnalorphine: definition of N-allyl conformation for antagonism at the opiate receptor. J Med Chem. 1982 Nov;25(11):1278-80.		
	C41	KOCZKA, et al., Acta Chimica Academica Scien. Hung. (1967) 51(4), 393-02		

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/821,813	ATTY. DOCKET NO.: P0453.70112US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: April 8, 2004	CONFIRMATION NO.: Not Yet Assigned
	APPLICANT: Boyd et al.	
Sheet 4 of 6	GROUP ART UNIT: Not Yet Assigned	EXAMINER: Not Yet Assigned

	C42	KOOB et al., Effects of opiate antagonists and their quaternary derivatives on heroin self-administration in the rat. J Pharmacol Exp Ther. 1984 May;229(2):481-6.		
	C43	KOTAKE et al., Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica. 1989 Nov;19(11):1247-54.		
	C44	KROMER et al., Endogenous opioids, the enteric nervous system and gut motility. Dig Dis. 1990;8(6):361-73. Review.		
	C45	KROMER et al., The current status of opioid research on gastrointestinal motility. Life Sci. 1989;44(9):579-89. Review.		
	C46	LEANDER, A kappa opioid effect: increased urination in the rat. J Pharmacol Exp Ther. 1983 Jan;224(1):89-94.		
	C47	LITTLE, et al., Society for Neuroscience Abstracts, 27 (2); 2001, p. 2407		
	C48	LIVINGSTON et al., Postoperative ileus. Dig Dis Sci. 1990 Jan;35(1):121-32. Review.		
	C49	LYDON et al., ESA Free Paper Prize Competition. Eur J Anaesthesiol. 2001 Apr;18 Suppl 21:92.		
	C50	LYSLE et al., Modulation of immune status by a conditioned aversive stimulus: evidence for the involvement of endogenous opioids. Brain Behav Immun. 1992 Jun;6(2):179-88.		
	C51	MAGNAN et al., The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn Schmiedebergs Arch Pharmacol. 1982 Jun;319(3):197-205.		
	C52	MANARA, et al., Adv. Endog. Exog. Opioids, Poroc. Int. Narc. Res. Conf., 12th (1981), 402-4		
	C53	MANARA et al., The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol. 1985;25:249-73. Review.		
	C54	MICKLEY et al., Quaternary naltrexone reverses morphine-induced behaviors. Physiol Behav. 1985 Aug;35(2):249-53.		
	C55	MISRA et al., Intravenous kinetics and metabolism of [15,16-3H]naltrexonium methiodide in the rat. J Pharm Pharmacol. 1987 Mar;39(3):225-7.		
	C56	MOERMAN et al., Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences. Acta Anaesthesiol Belg. 1995;46(3-4):127-32.		
	C57	MOSS, et al., N. Engl. J. Med., (2002) 346 (6), 455		
	C58	MUCHA, Is the motivational effect of opiate withdrawal reflected by common somatic indices of precipitated withdrawal? A place conditioning study in the rat. Brain Res. 1987 Aug 25;418(2):214-20.		
	C59	MUCHA, Taste aversion involving central opioid antagonism is potentiated in morphine-dependent rats. Life Sci. 1989;45(8):671-8.		
	C60	MURPHY et al., Anesthesiology, Sept. (1999), 91 (3A) p. A349 (Abstract)		
	C61	MURPHY et al., Pharmacokinetic profile of epidurally administered methylnaltrexone, a novel peripheral opioid antagonist in a rabbit model. Br J Anaesth. 2001 Jan;86(1):120-2.		
	C62	MURPHY et al., American Society of Anesthesiologists 1999 annual meeting. Dallas, Texas, USA. October 9-13, 1999. Abstracts. Anesthesiology. 1999 Sep;91(3A Suppl):A349.		
	C63	MURPHY et al., Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology. 1997 Oct;87(4):765-70.		
	C64	MURPHY et al., Opioid antagonist modulation of ischaemia-induced ventricular arrhythmias: a peripheral mechanism. J Cardiovasc Pharmacol. 1999 Jan;33(1):122-5.		
	C65	NARANJO et al., Evidence for a central but not adrenal, opioid mediation in hypertension induced by brief isolation in the rat. Life Sci. 1986 May 26;38(21):1923-30.		
	C66	NELSON, Dissertation Abstracts International, (62/03-B), p. 1635 (Abstract)		
	C67	ODIO et al., Central but not peripheral opiate receptor blockade prolonged pituitary-adrenal responses to stress. Pharmacol Biochem Behav. 1990 Apr;35(4):963-9.		
	C68	OSINSKI et al., Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):251-9.		
	C69	PAPPAGALLO, Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001 Nov;182(5A Suppl):11S-18S. Review.		
	C70	POLAK et al., Enkephalin-like immunoreactivity in the human gastrointestinal tract. Lancet. 1977 May 7;1(8019):972-4.		
	C71	POWELL et al., Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther. 2002 Feb;300(2):588-96.		
	C72	QUOCK, et al, J. Bioelectr. (1986), 5(1), 35-46		

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/821,813	ATTY. DOCKET NO.: P0453.70112US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: April 8, 2004	CONFIRMATION NO.: Not Yet Assigned
	APPLICANT: Boyd et al.	
Sheet 5 of 6	GROUP ART UNIT: Not Yet Assigned	EXAMINER: Not Yet Assigned

	C73	QUOCK et al., Narcotic antagonist-induced hypotension in the spontaneously hypertensive rat. Life Sci. 1985 Sep 2;37(9):819-26.		
	C74	QUOCK et al., Narcotic antagonist potentiation of apomorphine drug effect: a stereospecific, centrally mediated drug action. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(3):239-43.		
	C75	RAMABADRAN, Effects of N-methylnaloxone and N-methylnaltrexone on nociception and precipitated abstinence in mice. Life Sci. 1982 Sep 20-27;31(12-13):1253-6.		
	C76	RIVIÈRE et al., Fedotozine reverses ileus induced by surgery or peritonitis: action at peripheral kappa-opioid receptors. Gastroenterology. 1993 Mar;104(3):724-31.		
	C77	ROBINSON et al., Oral naloxone in opioid-associated constipation. Lancet. 1991 Aug 31;338(8766):581-2.		
	C78	ROGER et al., Colonic motor responses in the pony: relevance of colonic stimulation by opiate antagonists. Am J Vet Res. 1985 Jan;46(1):31-5.		
	C79	RUSSELL et al., Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol. 1982 Mar 12;78(3):255-61.		
	C80	SCHAEFER et al., Effects of opioid antagonists and their quaternary derivatives on locomotor activity and fixed ratio responding for brain self-stimulation in rats. Pharmacol Biochem Behav. 1985 Nov;23(5):797-802.		
	C81	SCHANG et al., Beneficial effects of naloxone in a patient with intestinal pseudoobstruction. Am J Gastroenterol. 1985 Jun;80(6):407-11.		
	C82	SCHANG et al., How does morphine work on colonic motility? An electromyographic study in the human left and sigmoid colon. Life Sci. 1986 Feb 24;38(8):671-6.		
	C83	SCHILLER et al., Studies of the mechanism of the antidiarrheal effect of codeine. J Clin Invest. 1982 Nov;70(5):999-1008.		
	C84	SCHMIDHAMMER, et al., Helv. Chim. Acta (1994), Vol. 77, No. 6, p. 1585-9		
	C85	SCHMIDHAMMER, et al., Helv. Chim. Acta. (1993) No. 1, p. 476-80		
	C86	SCHOLZ, 2000, 63 (6) p. 103		
	C87	SCHREIER et al., Central regulation of intestinal function: morphine withdrawal diarrhea. Proc West Pharmacol Soc. 1982;25:151-4.		
	C88	SOLVASON et al., Naltrexone blocks the expression of the conditioned elevation of natural killer cell activity in BALB/c mice. Brain Behav Immun. 1989 Sep;3(3):247-62.		
	C89	SWAN, et al., AIDS Research, NIDA Notes, (1995), 10(3), 1-6		
	C90	SYKES, Oral naloxone in opioid-associated constipation. Lancet. 1991 Jun 15;337(8755):1475.		
	C91	TAGUCHI et al., Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med. 2001 Sep 27;345(13):935-40.		
	C92	THOMPSON et al., Opioid stimulation in the ventral tegmental area facilitates the onset of maternal behavior in rats. Brain Res. 1996 Dec 16;743(1-2):184-201.		
	C93	UKAI et al., Suppression of deprivation-induced water intake in the rat by opioid antagonists: central sites of action. Psychopharmacology (Berl). 1987;91(3):279-84.		
	C94	VALENTINO et al., Quaternary naltrexone: evidence for the central mediation of discriminative stimulus effects of narcotic agonists and antagonists. J Pharmacol Exp Ther. 1981 Jun;217(3):652-9.		
	C95	VALENTINO et al., Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. Life Sci. 1983 Jun 20;32(25):2887-96.		
	C96	WALKER, et al., Psychopharmacology (1991), 104(2), p. 164-6		
	C97	WARREN et al., Effects of quaternary naltrexone and chlordiazepoxide in squirrel monkeys with enhanced sensitivity to the behavioral effects of naltrexone. J Pharmacol Exp Ther. 1985 Nov;235(2):412-7.		
	C98	WILLETTE, et al., Res. Commun. Subst. Abuse (1983), 4(4), 325-37		
	C99	YUAN et al., Drug Dev. Res. (2000) 50(2), 133-141		
	C100	YUAN et al., Gastric effects of methylnaltrexone on mu, kappa, and delta opioid agonists induced brainstem unitary responses. Neuropharmacology. 1999 Mar;38(3):425-32.		
	C101	YUAN et al., Anesthesiology, Sept. (1995), 83 (3A), p A358 (Abstract)		
	C102	YUAN et al., Anesthesiology, Sept. (1995), 83 (3A), p A360 (Abstract)		
	C103	YUAN et al., Anesthesiology, Sept. (1999), 91 (3A) p. A973 (Abstract)		
	C104	YUAN et al., Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 2000 Apr;67(4):398-404.		
	C105	YUAN et al., The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 1997 Apr;61(4):467-75.		

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/821,813	ATTY. DOCKET NO.: P0453.70112US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: April 8, 2004	CONFIRMATION NO.: Not Yet Assigned
				APPLICANT: Boyd et al.	
Sheet	6	of	6	GROUP ART UNIT: Not Yet Assigned	EXAMINER: Not Yet Assigned

	C106	YUAN et al., Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther. 1996 Apr;59(4):469-75.		
	C107	YUAN, et al., Clinical Pharmacology & Therapeutics (1995) 57(2), p. 138		
	C108	YUAN et al., Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend. 1998 Oct 1;52(2):161-5.		
	C109	YUAN et al., Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. Eur J Pharmacol. 1995 Mar 24;276(1-2):107-11.		
	C110	YUAN et al., Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther. 2002 Jan;300(1):118-23.		
	C111	YUAN et al., Oral methylnaltrexone for opioid-induced constipation. JAMA. 2000 Sep 20;284(11):1383-4.		
	C112	YUAN et al., Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000 Jan 19;283(3):367-72.		
	C113	YUAN et al., Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain. 1999 Dec;83(3):631-5.		
	C114	YUAN et al., Effects of methylnaltrexone on chronic opioid induced gut motility and transit time changes. Br J Anaesth. 1998;81(1):94.		
	C115	YUAN et al., Effects of methylnaltrexone on chronic opioid-induced gut motility and transit time changes. University of Leicester – Abstracts from the Eighth International Symposium on Pain, Anaesthesia and Endocrinology. 1997 September 18-19th.		
	C116	[No Author Listed] Oncology. 1996;10(12):1880.		

EXAMINER	DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __ , filed __ , and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]